Abstract
The negative impact of chronic inflammation on the onset and progression of endothelial dysfunction, blood pressure destabilization and renal function deterioration is widely discussed by modern researchers. One of the topical lines of research is studying the effect of osteoarthritis (OA) on the course of chronic heart failure (CHF). Using modern immunological cytokines in the treatment of such patients can contribute to an earlier diagnosis of the risk of decom-pensation of the cardiovascular pathology. The aim of the study. To study the possibilities of using galectin-3 in CHF patients with preserved and moderately reduced left ventricular ejection fraction and osteoarthritis in combination with CHF decompensation factors. Materials and methods. A cross-sectional study of 107 CHF patients was carried out: 60 patients formed the study group with combination of CHF and OA; 47 patients were included in comparison group with CHF and without OA. A comparative analysis of clinical, laboratory and instrumental parameters, as well as of the galectin-3 level was car-ried out. The relationship between galectin-3 and CHF decompensation factors in the study group was analyzed, and its diagnostic capabilities were assessed. Statistical processing was carried out using the Statistica 10.0 program (StatSoft Inc., USA). The critical level of statistical significance was p < 0.05. Results. According to the results of the study, in the study group, a statistically significantly higher level of galectin-3 was revealed compared to the one in patients of the comparison group – 42 ± 2.2 and 20 ± 1.5 ng/ml respectively (p < 0.001), as well as statistically significant associations of galectin-3 with blood pressure levels, dyslipidemia, esti-mated glomerular filtration rate, and atrial natriuretic peptide. Conclusion. The presence of a statistically significant association of galectin-3 with CHF decompensation factors in patients with osteoarthritis reveals new pathogenetic features of the course of this comorbid pathology. Apparently, it is possible to use galectin-3 as a marker for diagnosing decompensation in this group of patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
